BU-CY is the established non-TBI-based myeloablative conditioning regimen for allogeneic hematopoietic SCT. However, liver toxicity and hepatic veno-occlusive disease (VOD) are frequent life-threatening complications. Pharmacological considerations suggest that BU can trigger toxicity of subsequent CY. Recent animal data confirmed this hypothesis. Less liver toxicity and better outcomes were observed when mice were treated with the reversed order of CY and BU. We analyzed in this study liver toxicity and outcome in patients receiving BU-CY (16 patients) or CY-BU (59 patients). Liver function differed significantly with higher levels of liver function tests between day þ 10 and þ 30, and a higher cumulative incidence of VOD in the BU-CY cohort (2/16 (12.5%) vs 0/59 (0%), P ¼ 0.006). TRM was significantly higher in patients receiving BU-CY (cumulative incidence BU-CY 45%, CY-BU 17%, P ¼ 0.02), without yet translating into a significant survival difference (incidence for survival: BU-CY 38%, CY-BU 63%; hazard ratio 1.19 for BU-CY, 95% confidence interval 0.29-4.82, P ¼ 0.80). Rates of engraftment and relapse were not different. These data support the concepts derived from animal models in favor of CY-BU compared with traditional BU-CY and form the basis for prospective controlled comparisons.
Introduction BU-CY is the established non-TBI-based myeloablative conditioning regimen for allogeneic hematopoietic SCT (HSCT). The antileukemic and immunosuppressive efficacy of BU-CY is considered to be equivalent to or even better than that of TBI in combination with CY. [1] [2] [3] The introduction of i.v. BU offered the advantage of easier administration with predictable pharmacokinetics and better tolerance than oral BU. However, liver toxicity and hepatic veno-occlusive disease (VOD) are the most frequent life-threatening complications observed after high-dose BU. [4] [5] [6] BU and CY are mainly metabolized in the liver. Interactions between these two drugs and with other commonly used drugs have been reported and are decisive for drug-related toxicity. [7] [8] [9] Clinical studies showed an increased liver toxicity, scored by the development of VOD and total serum bilirubin levels, nonrelapse mortality and overall survival after HSCT in patients with increased exposure to toxic metabolites of CY. 10 It could also be shown that BU profoundly affects the metabolism of CY with higher levels of toxic metabolites of CY. 11, 12 Pharmacological studies demonstrated that treatment with BU can decrease the levels of glutathione, a central player in the metabolism of toxic CY metabolites, in hepatocytes. 13, 14 Furthermore, conditioning with BU-CY induced higher levels of liver enzymes and inflammatory cytokines. 15 This observation is important, because the proinflammatory cytokines, particularly IL-2 and TNF-a, may be one of the first steps in the development of acute GVHD. [16] [17] [18] These theoretical considerations and pharmacological data indicate that application of BU may trigger liver toxicity of subsequent CY, and suggest that the reverse order of CY-BU would be preferable. This was suggested several years ago in a mouse model 15 and in a pediatric study of autologous HSCT, in which BU induced less liver toxicity when given as the second drug. 9 Recent animal data confirmed this hypothesis, 19 showing less liver toxicity and better outcomes when mice were treated with CY-BU. While CY-BU was not feasible in patients with oral BU in view of the high emetogenic potential of CY, it has become a possibility with the introduction of i.v. BU. We were therefore interested in exploring this concept and changed the order of drug application to CY-BU in 2006 in selected patients.
We now retrospectively compared liver toxicity and transplantation outcomes in patients given either BU-CY or CY-BU in this single-centre cohort study.
Patients and methods

Study design
This retrospective cohort study is based on standardized, prospectively collected clinical data from the database of the Division of Hematology at the University Hospital of Basel, Switzerland, supplemented by a chart review of clinical records. Data on liver function were collected from the database of the Laboratory at the University Hospital of Basel, Switzerland. All patients gave written informed consent to their treatment and to the analysis of transplant outcome data.
Two cohorts were compared regarding liver toxicity and transplantation outcomes: BU-CY cohort, BU followed by CY, or CY-BU cohort, CY followed by BU as conditioning regimen.
This pilot study was initiated with the introduction of i.v. BU (Busilvex, Robapharm/Pierre Fabre SA, Allschwil, Switzerland) in 2003. The order of application from BU-CY to CY-BU was changed during 2006. For logistic reasons, during the first year not all patients received CY followed by BU after this change. Patients treated on formal multicentre protocols remained on BU-CY.
Patient population
Between 1st January 1993 and 31st December 2008, 93 patients received an allogeneic HSCT after standard conditioning regimen with a BU and CY containing regimen at the stem cell transplant unit of the University Hospital Basel, Switzerland. In the BU-CY cohort patients received oral BU (18 patients) or i.v. BU (16 patients) followed by i.v. CY. The 59 patients with the CY-BU regimen received i.v. CY followed by i.v. BU. For reasons of cohort homogeneity, the 18 patients receiving oral BU were excluded from the analysis. Data are presented on the remaining 75 patients. The patient characteristics are summarized in Table 1 . There were slightly more male patients (57.3%) and age ranged from 18 to 70 years (median age 49 years). For a third of the patients it was the second or third allogeneic HSCT. 20 Indications for transplantation were hematological malignancies (acute leukaemia 50.7%, chronic myelogenous leukaemia 13.3%, myelodysplastic syndrome and myeloproliferative neoplasia 28.0%, lymphoproliferative disorders 4.0%) or other diseases (4.0%). Donors were HLA-identical siblings (48.0%), other family members (2.7%) or a matched unrelated donor (49.3%). Pretransplant characteristics were comparable in the two cohorts for gender, age, underlying disease, stage, stem cell source, donor type and EBMT risk score. 21 Patients receiving CY-BU were more likely to be transplanted in more recent years (year of transplantation in the BU-CY cohort [2003] [2004] [2005] [2006] , in the CY-BU cohort 2006-2008), and had less frequently received a previous allogeneic HSCT and previous TBI as BU-CY patients.
Conditioning regimen and supportive-care measures
The BU-CY conditioning regimen consisted of i.v. BU 0.8 mg/kg administered every 6 h (16 doses) on days À7 to À4, followed by i.v. CY 60 mg/kg on days À3 and À2. Pharmacokinetic and pharmacodynamic analyses for BU levels were not performed. The GVHD prophylaxis was identical in both cohorts and consisted of CYA from day À1 and MTX on days 1, 3 and 6. Patients also received phenytoin or lorazepam prophylaxis for BU-related central nervous system adverse reactions. Basic transplant strategies as well as supportive care measures were equal for both cohorts and remained unchanged during the study period.
22,23
Definitions The diagnosis of VOD was based on the presence of two of the three clinical manifestations according to the Seattle criteria (hyperbilirubinaemia and painful hepatomegaly or fluid retention). 24 High-risk situation for VOD was defined, according to our institutional guidelines, by the presence of at least three risk factors: multiple chemotherapy regimens in the past, abnormal liver function tests before transplantation, donor or patient with positive serology for CMV, unrelated or HLA-mismatched donor, allogeneic HSCT and conditioning regimen with BU; the last two risk factors were present in all patients. Patients at high risk for VOD, who received prophylaxis with heparin and ursodeoxycholic acid, were 14 (87.5%) in the BU-CY cohort vs 50 (84.7%) in the CY-BU cohort (P ¼ 0.78). Patients with diagnosis of VOD were treated with defibrotide. 25 Myeloid engraftment was conventionally defined as the first of three consecutive days on which the patient presented an absolute peripheral blood neutrophil count of 0.5 Â 10 9 /l or more. 26 Incidence, severity and organ involvement of acute GVHD was assessed daily according to established criteria. 27, 28 Whenever possible, diagnosis of acute GVHD was confirmed by skin or gut biopsy.
Laboratory analysis
Liver function was measured by routine photometric assay (in accordance with the procedures of the International Federation of Clinical Chemistry) 29 for levels of bilirubin and liver enzymes (aspartate amino transferase, alanine amino transferase, gamma-glutamyl transpeptidase and alkaline phosphatase) on day À8 (before starting the conditioning regimen), 0, þ 10, þ 20 and þ 30. Chimerism analysis of peripheral blood at appropriate intervals after HSCT was performed by PCR-based analysis of STRs as described previously.
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Statistical analysis End points were liver function and VOD, relapse, incidence, severity and organ involvement of acute GVHD, TRM and survival. Day 0 was defined as the day of transplantation. Liver function tests were compared using the non-parametric Mann-Whitney U-test. In the univariate analysis cumulative incidences of acute GVHD, relapse and TRM were calculated by treating death from any cause as a competing outcome, and were compared using the Gray test. Engraftment and survival were compared using the log rank test. The different transplant outcomes (acute GVHD, TRM, relapse, survival) were additionally analysed using a Cox regression model, adjusting for disease, EBMT score, previous HSCT or TBI, and application order of CY and BU.
Patient and transplant characteristics were compared using Pearson's chi-square, Fisher's exact test or MannWhitney U-test, as appropriate. Two-sided P-values o0.05 were considered significant.
Results
Engraftment
One patient (incidence 6.3%) in the BU-CY cohort and one (incidence 1.7%) in the CY-BU cohort failed to engraft (P ¼ 0.06). Times to myeloid engraftment (BU-CY cohort median 12 days (range 11-22) vs CY-BU cohort median 14 days (range 10-44)) were similar between the patients of the two cohorts (P ¼ 0.09). Chimerism analysis by PCR-based analysis of STRs was done in 58 of 75 patients (77%, 4 patients in the BU-CY cohort and 54 patients in the CY-BU cohort), showing 100% of donor chimerism at day 100 post transplantation in 3 patients (75%) in the BU-CY cohort and in 54 patients (100%) in the CY-BU cohort.
Liver toxicity Liver function tests were not different between cohorts at baseline with the exception of slightly higher levels of bilirubin in patients receiving CY-BU (median of 8.5 mmol/l in the BU-CY cohort vs 12.0 mmol/l in the CY-BU cohort, P ¼ 0.02). In contrast, median values of bilirubin, aspartate amino transferase and alanine amino transferase were all statistically significantly higher in the BU-CY cohort between day þ 10 and þ 30 ( Figure 1) . Levels of gamma-glutamyl transpeptidase and alkaline phosphatase showed a similar trend between the two cohorts. Diagnosis of VOD was made in 2 of 16 patients in the BU-CY cohort (cumulative incidence at day 100 12.5%, 95% confidence interval (CI) 0-29%) but in none (0%) of the CY-BU cohort (P ¼ 0.006). For these two patients it was the first SCT. They died after developing VOD.
Acute GVHD
The cumulative incidence for acute GVHD at day 100 was 75% (95% CI 52-98%) in the BU-CY cohort and 44% (95% CI 31-57%) in the CY-BU cohort (P ¼ 0.001), with a higher relative risk for acute GVHD for BU-CY in the multivariate analysis (hazard ratio (HR) 4.33, 95% CI 1.88-9.95, P ¼ 0.001). Significant differences for organ distribution of acute GVHD could also be found: the cumulative incidence for acute GVHD at day 100 for skin affection was 63% (95% CI 29-97%) in the BU-CY cohort vs 37% (95% CI 25-50%) in the CY-BU cohort (HR 4.36 for BU-CY, 95% CI 1.75-10.88; P ¼ 0.002), for gut affection 50% (95% CI 24-76%) vs 19% (95% CI 10-30%) (HR 5.49 for BU-CY, 95% CI 1.49-20.24; P ¼ 0.01), and for liver affection 19% (95% CI 0-49%) vs 5% (95% CI 1-13%) (HR 30.11 for BU-CY, 95% CI 2.16-419.67; P ¼ 0.01). Severity of acute GVHD was not different between the two cohorts, with a median grade for overall Toxicity in patients receiving BU-CY compared with CY-BU N Cantoni et al acute GVHD of 2 (range 1-4) in both cohorts (P ¼ 0.08), for skin involvement of 2 (range 1-4) in the BU-CY cohort vs 2 (range 1-3) in the CY-BU cohort (P ¼ 0.06), for gut involvement of 1 (range 1-4) in both cohorts (P ¼ 0.72), and for liver involvement of 1 (range 1-2) in the BU-CY cohort vs 1 (range 1-3) in the CY-BU cohort (P ¼ 1.00).
Survival and relapse
The cumulative incidence of TRM at 2 years was significantly higher in patients receiving BU-CY (BU-CY 45% (95% CI 20-70%), CY-BU 17% (95% CI 7-27%), P ¼ 0.02) (Figure 2a) . This difference remained significant after adjustment for all key risk factors in the multivariate analysis ( Table 2) . Causes of TRM in the BU-CY cohort were liver toxicity (2 patients, 13%), infections (2 patients, 13%) and GVHD (3 patients, 19%) , and those in the CY-BU cohort were GVHD (7 patients, 12%) and infections (3 patients, 5%). Both approaches were equally effective in leukaemia control, with no differences in the cumulative incidence of relapse (BU-CY 19% (95% CI 0-39%) vs CY-BU 20% (95% CI 9-31%)) and a similar relative risk for relapse in the multivariate analysis ( Table 2) .
The difference between the two cohorts for TRM with similar relapse rates translated into a higher but not yet significant overall survival probability in patients after conditioning regimen with CY-BU (probability of survival: BU-CY 38%, 95% CI 19-71%; CY-BU 63%, 95% CI 51-77%) ( Figure 2b and Table 2 ).
Discussion
This retrospective single-centre study provides some clear objective data. The order of application of BU and CY in the traditional BU-CY myeloablative conditioning regimen is of clinical significance. Patients given BU after CY had lower liver function test values and more frequently normal values in the early post-transplant period. So far, none of these patients have developed VOD; they had a lower incidence of acute GVHD and a lower TRM. Rate of engraftment, time to engraftment and rate of relapse were not different between the two cohorts when adjusted for the Toxicity in patients receiving BU-CY compared with CY-BU N Cantoni et al key risk factors. Hence, this reduced toxicity did translate directly into a trend for better overall survival. Interestingly, these results were similar if the analysis was performed including in the BU-CY cohort the 18 patients receiving oral BU.
These observations were not obtained as a chance phenomenon. They were based on a clear hypothesis that the order of application of BU and CY could have an impact on outcome after allogeneic HSCT. This concept is based on pharmacological and clinical data showing that previous application of BU may delete glutathione levels in hepatocytes and trigger release of proinflammatory cytokines. The impact of BU-CY order of application on liver toxicity was recently confirmed by Sadeghi et al. 19 in their animal model. Less liver toxicity and better outcomes were observed in mice treated with CY-BU.
The limitation of our study is the retrospective design based on the comparison with an historical group of patients, however with comparable pretransplant characteristics except for the higher number of patients with previous allogeneic HSCT and TBI in the BU-CY cohort.
In conclusion, our data support the concept in favour of CY-BU compared with the traditional BU-CY. They form the basis for prospective controlled studies. Cox model adjusted for disease, EBMT score, previous HSCT or total body irradiation, and application order of CY and BU.
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